<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02260050</url>
  </required_header>
  <id_info>
    <org_study_id>262.284</org_study_id>
    <nct_id>NCT02260050</nct_id>
  </id_info>
  <brief_title>Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers</brief_title>
  <official_title>Bioequivalence of 20 mg of the New Formulation of WAL 801 CL Dry Syrup Compared to 20 mg of the Conventional Formulation of WAL 801 CL Dry Syrup Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, 2x2 Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To establish the bioequivalence of the new formulation of WAL 801 CL dry syrup vs. the
      conventional formulation of WAL 801 CL dry syrup
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to last measurable concentration (AUC0- tz)</measure>
    <time_frame>up to 34 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analytes in plasma (Cmax)</measure>
    <time_frame>up to 34 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 34 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration of the analyte in plasma (tmax)</measure>
    <time_frame>up to 34 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant of the analyte in plasma (λz)</measure>
    <time_frame>up to 34 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>up to 34 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body after po administration (MRTpo)</measure>
    <time_frame>up to 34 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 34 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant findings in physical examination</measure>
    <time_frame>up to 34 hours after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant findings in vital signs</measure>
    <time_frame>Up to 34 hours after last drug administration</time_frame>
    <description>blood pressure, pulse rate, body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 48 hours after last drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>WAL 801 CL new formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WAL 801 CL conventional formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WAL 801 CL dry syrup new formulation</intervention_name>
    <arm_group_label>WAL 801 CL new formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WAL 801 CL dry syrup conventional formulation</intervention_name>
    <arm_group_label>WAL 801 CL conventional formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males according to the following criteria:

               -  Based upon a complete medical history, including the physical examination, vital
                  signs (blood pressure (BP), pulse rate (PR), body temperature (BT)), 12-lead ECG,
                  clinical laboratory tests (including gastric acidity (GA) test)

               -  No finding of clinical relevance

               -  No evidence of a clinically relevant concomitant disease

          -  Age ≥ 20 and Age ≤ 35 years

          -  BMI ≥ 18.5 and BMI ≤ 25 kg/m2 (Body Mass Index)

          -  Signed and dated written informed consent prior to Screening Phase and prior to
             Treatment Phase (Day -1 in Treatment period 1) in accordance with Japanese Good
             Clinical Practice (GCP)

        Exclusion Criteria:

          -  Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  History of surgery of gastrointestinal tract with the exception of appendectomy

          -  History of (and/or current) diseases of the central nervous system (such as epilepsy)
             or psychiatric disorders or neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Current chronic or relevant acute infections

          -  History of hypersensitivity (including drug allergy) or current allergic disorders
             which are deemed relevant to the trial by the investigator or the sub-investigators;
             e.g. bronchial asthma, allergic rhinitis, atopic dermatitis and food allergy
             (excluding asymptomatic seasonal rhinitis/hay fever)

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to drug administration and during
             Treatment Phase

          -  Use of any drugs which might reasonably influence the results of the trial based on
             the knowledge at the time of protocol preparation, within 10 days prior to
             administration and during Treatment Phase

          -  Participation in Phase I trial of new chemical entities within 4 months prior to drug
             administration and during the trial, or in another clinical trial within 3 months
             prior to drug administration and during Treatment Phase

          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)

          -  Inability to refrain from smoking during hospitalization

          -  Alcohol abuse (more than 60 g/day) (confirmed by interview)

          -  Drug abuse (confirmed by interview)

          -  Whole blood donation (400 mL within 3 months or more than 100 mL within 4 weeks prior
             to drug administration or during the trial) or component blood donation (within 2
             weeks prior to drug administration or during Treatment Phase)

          -  Excessive physical activities (within 48 hours prior to each treatment period and
             during hospitalisation)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of study centre
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

